BiovaxID: On the Trail of the Follicular Lymphoma Vaccine (Part 1)

Earlier this month, the biopharmaceutical company Biovest had a meeting with the FDA to discuss the therapeutic lymphoma vaccine BiovaxID.

Shortly after the meeting, Biovest issued a press release about the meeting, details of which they also included in an SEC filing. The FDA dealt the company a blow in their bid to gain regulatory approval for BiovaxID in the US by requiring the company to run another Phase III confirmatory trial.

The company is seeing results with their efforts to bring this therapeutic vaccine to Canada and to the European Union. Despite the recent tendency of the FDA's Office of Oncology Drug Products to rubber-stamp the overwhelming majority of cancer drugs that make their way to Washington, they opted to require more from Biovest than we've seen them require from other companies and in many cases the sub-standard treatments those other companies presented to the agency.

BiovaxID offers the follicular lymphoma patient an enormous, long-term survival and quality of life benefit as consolidation therapy following induction treatment, the kind of benefit not seen before in lymphoma.

In other words, the problem here is not the product; the problem, I believe, is in the myopic vision of regulators at the FDA.

On The Trail

Therefore, in this multi-part series "BiovaxID: On the Trail of the Follicular Lymphoma Vaccine", I'll look at the issue from a variety of angles:

-- I'll look at the FDA's recent history of approving cancer treatments.

-- I'll look at existing trial data for BiovaxID.

-- I'll talk with the principles at Biovest, including their CEO and their Chief Science Officer, to learn more about the science and the benefits of BiovaxID.

-- I'll talk with two of the chief clinical investigators of BiovaxID, Dr. Larry Kwak, Chairman, Department of Lymphoma/Myeloma at MD Anderson in Houston, and Dr. Eduardo Sotomayor, who holds the Susan and John Sykes Endowed Chair in Hematologic Malignancies at Moffitt Cancer Center in Florida.

-- And I'll also (I hope) be speaking with one or more of the patients who participated in the clinical trials for BiovaxID to find out about their experiences.

When finished I hope to have presented a solid explanation of how this lymphoma vaccine can improve the daily lives of patients with follicular lymphoma, and even mantle cell lymphoma, in a language all of us can understand.

BiovaxID: On the Trail of the Lymphoma Vaccine

Follow the links below to read the rest of this series:

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...